| Market Cap | $253.12M-33.6% |
| Revenue (ttm) | $49.83M |
| Net Income | -$72.22M |
| EPS | -$0.54 |
| Shares Out | 154.34M |
| PE Ratio | n/a |
| Forward PE | -2.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,679,287 |
| Open | $1.69 |
| Previous Close | $1.71 |
| Day's Range | $1.63 - $1.78 |
| 52-Week Range | $1.63 - $3.94 |
| Beta | 2.08 |
| Analysts | Buy |
| Price Target | $6.10(+271.95%) |
| Earnings Date | Nov 9, 2026 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating EDIT in the last 3 months, one vote each. Issuer-paid research is not counted.
$EDIT stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of EDIT by members of U.S. Congress
| Donna ShalalaHouse | Sale$1.00K – $15.00K | Jun 4, 2019 |
| Donna ShalalaHouse | Purchase$1.00K – $15.00K | Mar 6, 2019 |
Recently reported changes in EDIT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EDIT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EDIT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
EDIT Revenue by Segment
| Intellectual property and patent related fees | $6.06M | 55.39% |
| Sublicense and license fees | $4.88M | 44.61% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New EDIT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EDIT from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from EDIT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive gene therapy trial data showing 90% LDL reduction plus revenue beat offset by Q3 loss; concrete clinical progress outweighs financial headwinds.
Recent Insider Activity
Insider Score Trend Over Time
-59.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| WDNA | WisdomTree BioRevolution Fund | 0.66% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.44% |
| MEDX | Horizon Kinetics Medical ETF | 0.30% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.29% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.24% |
| GNOM | Global X - Genomics & Biotechnology ETF | 0.18% |
| STSB | iShares Factors US Small Blend Style ETF | 0.15% |
| XBI | State Street SPDR S&P Biotech ETF | 0.09% |
| IWC | iShares Micro-Cap ETF | 0.09% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.03% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.02% |
Weight is the stock’s share of each fund’s holdings.
